BiotechTube

cisplatin + doxorubicin hydrochloride + etoposide + ifosfamide + methotrexate + zoledronic acid

Phase 3Active
0 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sarcoma

Conditions

Sarcoma

Trial Timeline

Mar 1, 2007 → Dec 1, 2026

NCT ID
NCT00470223

About cisplatin + doxorubicin hydrochloride + etoposide + ifosfamide + methotrexate + zoledronic acid

cisplatin + doxorubicin hydrochloride + etoposide + ifosfamide + methotrexate + zoledronic acid is a phase 3 stage product being developed by Chugai Pharmaceutical for Sarcoma. The current trial status is active. This product is registered under clinical trial identifier NCT00470223. Target conditions include Sarcoma.

What happened to similar drugs?

1 of 14 similar drugs in Sarcoma were approved

Approved (1) Terminated (1) Active (12)
🔄Abemaciclib + PlaceboEli LillyPhase 3
🔄Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IVEisaiPhase 3
🔄Olaratumab + Doxorubicin + PlaceboEli LillyPhase 3
🔄Trabectedin + Doxorubicin + IfosfamideJohnson & JohnsonPhase 3
❌LV305 + G305MerckPhase 3
✅Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/TenofovirMerckApproved
🔄ridaforolimus + PlaceboMerckPhase 3

Hype Score Breakdown

Clinical
17
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00470223Phase 3Active

Competing Products

20 competing products in Sarcoma

See all competitors
ProductCompanyStageHype Score
Tc99m-tilmanoceptNavidea BiopharmaceuticalsPhase 1
19
Azenosertib + GemcitabineZentalis PharmaceuticalsPhase 1/2
22
Olaratumab + Doxorubicin + Ifosfamide + MesnaEli LillyPhase 1
29
CAB-AXL-ADC + PD-1 inhibitorBioAtlaPhase 1/2
22
AbemaciclibEli LillyPhase 2
39
Abemaciclib + PlaceboEli LillyPhase 3
44
PLX3397 + sirolimusDaiichi SankyoPhase 1/2
24
exatecan mesylateDaiichi SankyoPhase 2
35
efatutazoneDaiichi SankyoPhase 2
35
soblidotinDaiichi SankyoPhase 2
35
exatecan mesylateDaiichi SankyoPhase 2
35
LinsitinibAstellas PharmaPhase 2
35
Fluzoparib+ DalpiciclibSun PharmaceuticalPhase 2
31
Anlotinib HydrochlorideSun PharmaceuticalPhase 2
31
Doxorubicin Hydrochloride Liposome+Irinotecan + Temozolomide+Irinotecan+VincristineSun PharmaceuticalPhase 2
42
irinotecan liposome (II) + temozolomide + fluzoparibSun PharmaceuticalPhase 2
42
Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IVEisaiPhase 3
40
EribulinEisaiPhase 2
39
Lenvatinib + Ifosfamide + Etoposide + LenvatinibEisaiPhase 2
35
Palonosetron - Single Dose + Palonosetron - Triple Dose + Adriamycin + Ifosfamide chemotherapy (AI) + Zinecard + Mesna + Vincristine + DexamethasoneEisaiPre-clinical
26